Compounded tirzepatide is the format microdosing happens in because every FDA-approved tirzepatide product is manufactured at six fixed strengths, with nothing between them. Microdosed tirzepatide at Telos Rx is prescribed only after review by a licensed provider.
Most explanations stop at marketing. The real answer sits in the prescribing information: the approved product set is a finite list, and an amount that is not on it is not a product anyone manufactures. This page covers why, what compounding is, and what not FDA-approved means for you.
The Approved Product Set Is a Finite List
Tirzepatide is a dual GIP and GLP-1 receptor agonist from Eli Lilly, sold as two FDA-approved brands of the same molecule: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.
Both are supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg. That is the entire approved range. There is no seventh strength and nothing between the steps. Those figures describe what the label authorises, not a recommendation for you; the ladder is covered in the tirzepatide dosage guide.
Every Brand Presentation Is Fixed, Including the Vials
This is where most articles get it wrong. The common claim is that brand tirzepatide comes only in pens and compounded only in vials, so vials are the flexible option. Not accurate.
The Mounjaro prescribing information lists prefilled single-dose pens, single-dose vials, multi-dose vials and KwikPens. Lilly ships vials too. The Zepbound prescribing information describes each single-dose pen or vial as containing a single fixed dose, and each multi-dose presentation as providing four doses of one strength.
So the constraint is not the container. It is the strength. A brand vial is still a manufactured strength from the same list of six, and swapping a pen for a vial does not create a dose the manufacturer never made. Handling and storage differences are covered in pens vs vials.
Why an In-Between Strength Does Not Exist
FDA approval is not granted to a molecule in the abstract. It goes to a specific product at specific strengths, supported by the trials that studied them. A manufacturer cannot simply add an intermediate strength to the box.
So the gap is structural, not commercial. Microdosing means prescribing below the standard labelled titration at a provider's discretion, and the approved catalogue contains no product built for that. Microdosing is not an FDA-approved concept: there is no approved microdose product, no approved microdose label, and therefore no official definition of what amount counts as a microdose. What counts is explored in what counts as a microdose of tirzepatide.
What Compounding Actually Is
Compounding is the preparation of a medication by a licensed pharmacist for an individual patient, against a prescription written for that person, under federal compounding regulations. It is long-established practice and predates the modern approval system.
According to FDA guidance on compounding, a drug may be compounded for a patient who cannot be treated with an approved medication, such as someone allergic to a dye in it, or a patient who cannot swallow a tablet. The through-line is a patient-specific need the approved catalogue does not fit.
Because the preparation is made rather than mass-produced, the prescriber can specify an amount outside the fixed brand increments, and it arrives as a vial with syringes. The measuring that follows is covered in tirzepatide dosing in mL.
If a provider-determined amount outside the fixed brand steps is what you are actually looking for, the next step is a written intake reviewed by a licensed provider. Microdosed tirzepatide at Telos Rx is as low as $116 per month as of publication, with flat pricing that does not change as your dose is adjusted.
See microdosed tirzepatideWhat Not FDA-Approved Means in Practice
This part deserves plain language rather than reassurance. Compounded tirzepatide is not FDA-approved. FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
A compounded preparation is also not a generic. A generic is approved after demonstrating equivalence to a brand product; a compounded preparation goes through no such review and need not match the brand's concentration or presentation.
Quality standards also differ by the setting where compounding occurs, and not every setting is held to the manufacturing standards that apply to approved drug production. None of this makes compounding illegitimate, but all of it is worth knowing first.
| FDA-approved tirzepatide (Mounjaro, Zepbound) | Compounded tirzepatide | |
|---|---|---|
| Regulatory status | FDA-approved | Not FDA-approved |
| Pre-market review of safety and effectiveness | Yes, by FDA | No; FDA does not verify these before marketing |
| Available strengths | Six labelled strengths only | Set by the prescription and the preparing pharmacy |
| Amounts between the labelled steps | Not manufactured | Possible, at a provider's direction |
| Same as a generic | Not applicable | No; a generic is approved, a compounded preparation is not |
| Primary day-to-day oversight | FDA | Generally state boards of pharmacy for state-licensed pharmacies |
FDA's Own Position on When Compounding Fits
Reporting this fairly means the unflattering part too. FDA's position is that compounded drugs should only be used in patients whose medical needs cannot be met by an approved drug, and that unnecessary use may expose patients to potentially serious health risks.
The agency also encourages people buying compounded medications through telehealth platforms to know who prepared the medication and whether that compounder is appropriately licensed. Fair questions to ask any provider, including this one.
Who Is Responsible for What
The provider decides whether tirzepatide is appropriate at all, reviews health history, medications and contraindications, determines the amount for that individual, and adjusts it over time. Everything is subject to medical approval by a licensed provider, and approval is not guaranteed.
The pharmacy prepares the medication against that prescription, sets the concentration and beyond-use date printed on your label, and meets the standards that apply to its licence. Telos Rx works with a network of licensed US compounding pharmacies, and the formulation can vary by state.
Candidacy is a clinical decision, not a checkout decision. Both brands carry a boxed warning about thyroid C-cell tumours seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Those cautions apply to compounded tirzepatide too, because the molecule is the same. What changes at lower amounts is in microdosing GLP-1 side effects.
What This Explanation Does Not Claim
None of this argues that compounded tirzepatide is better than brand, or that microdosing outperforms standard dosing. It explains why the format differs.
The pivotal trials, including the SURMOUNT and SURPASS programmes, studied the labelled dose range. There is no large randomised trial establishing the efficacy of microdosed tirzepatide. The rationale is pharmacological reasoning and clinical experience, not phase 3 evidence. Microdosing compounded tirzepatide sits outside the approved framework twice over: the preparation is not approved, and the use is not approved.
The honest summary is narrow. Compounding makes a provider-directed amount outside the fixed brand steps possible. It does not make that amount proven.
How Access Works at Telos Rx
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake and a licensed provider reviews it in writing, often within hours, without a scheduled appointment. If approved, the prescription goes to a licensed US compounding pharmacy with free 48-hour shipping. The service is LegitScript-certified, FSA and HSA eligible, available in all 50 states, and cancellable anytime. More in compounded tirzepatide via telehealth.
Keep Reading
- Microdose vs Standard Tirzepatide: How They Differ
- What Counts as a Microdose of Tirzepatide?
- Microdosing Tirzepatide vs Semaglutide: Compared
- Microdosing GLP-1 Side Effects: What Changes
- Telos Rx vs Noom Microdose: GLP-1 Programs Compared
- What Is Compounded Tirzepatide?
Frequently Asked Questions
Why is microdosing tirzepatide only available compounded?
Because the approved products are manufactured at six fixed strengths and nothing between them. A provider who wants an amount off that list cannot order it from the manufacturer, since it is not a product that exists. A compounding pharmacy prepares medication for an individual patient, so an amount outside the fixed steps becomes possible.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. It is prepared by licensed US compounding pharmacies under federal compounding regulations, against a prescription for an individual patient, and it always requires a prescriber.
Does Mounjaro or Zepbound come in a vial?
Yes. The prescribing information lists single-dose vials and multi-dose vials alongside the pens, so a vial does not automatically mean a compounded product. The difference that matters is not the container but the strength: every brand presentation is supplied at one of the six labelled strengths.
Is compounded tirzepatide the same as a generic?
No. A generic drug is approved by FDA after demonstrating equivalence to a brand product. A compounded preparation goes through no such approval, and is not required to match the brand concentration or presentation. The two are different regulatory categories, and the words are not interchangeable.
Is microdosing an approved use of tirzepatide?
No. Microdosing is not an FDA-approved concept. There is no approved microdose product and no approved microdose label, so there is no official definition of what amount counts as a microdose. It generally means prescribing below the standard labelled titration at a provider's discretion, decided case by case.
Is microdosing safer or more effective than standard dosing?
That is not established. The pivotal tirzepatide trials studied the labelled dose range, not sub-therapeutic amounts, and no large randomised trial has established microdose efficacy. The boxed warning about thyroid C-cell tumours in rodents and the contraindications apply either way, because the molecule is the same.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Wondering whether a provider-determined amount outside the fixed brand steps is reasonable for you? Start with the microdosed tirzepatide page, then complete the written intake at start.telosrx.com. A licensed provider reviews every request, and approval is not guaranteed.